- Metabolic Stability
- CYP Interaction
- Permeability & Transporters
- Physicochemical Properties
- Protein Binding
Discovery PK and Toxicology
Frontage offers a series of early discovery services that help sponsors with target discovery and validation, honing down on their lead compounds for development.
At Frontage, we offer a comprehensive portfolio of drug candidate evaluation services including DMPK, Safety and Toxicology, and Bioanalytical related services.
Our portfolio of Product Development and CMC services spans from drug discovery to the post approval phase, including lead compound quantification and analytical testing.
With over 20 years of experience in the execution of comprehensive Phase I-IIa studies, Frontage Clinical Services has completeed more than 20 studies.
Our next generation central laboratories provide a comprehensive range of laboratory testing, global logistics and project management services.
Frontage Laboratories, Inc. today announced that, through its wholly-owned subsidiary Frontage Europe S.r.l., it has completed the acquisition of the Bioanalytical and Drug Metabolism & Pharmacokinetics businesses of Accelera S.r.l (Accelera).
Accelera is a premier Contract Research Organization located in Nerviano, within the Lombardy region of Italy, part of the well-established NMS Group S.p.A. which has positioned itself as a global niche player in delivering discovery & preclinical studies and clinical bioanalysis to pharma and biotechnology companies, academic institutions, and other healthcare stakeholders.
Hosted by ISSX, Frontage's own Dr John Kapeghian discusses the "Cost Effective and Efficient Progression of Lead Drug Candidates to First in Human Studies in the Two Largest Economies in the World: USA and China."
Frontage offers various genetic toxicology services. Genotoxicity assessment is essential for the safety assessment of all types of substances, from pharmaceuticals, to food and agrochemical products. In general, the assessment of genotoxic hazards to humans follows a step-wise approach, beginning with a basic battery of in vitro tests followed in some cases by in vivo testing.
At Frontage, we offer extensive drug metabolism and pharmacokinetic capabilities for new chemical entities and compounds in development. We provide rapid turnaround of high-quality key DMPK data sets to support critical decisions in advancing potential therapeutic agents for further development. Our highly trained scientific staff applies state-of-the-art techniques and best-in-class approaches to provide broad and in-depth expertise/advice to clients on appropriate study designs, execution of studies, and interpretation of the data. DMPK studies can provide critical data during discovery and development of pharmaceutical and agrochemical products. Frontage’s DMPK services, performed in accredited facilities, can help support lead drug candidate or chemical selection, or help you meet specific regulatory requirements.
We know that to attract the best candidates we have to provide a stimulating and challenging work environment that gives our employees the opportunity to meet their career goals. We also recognize the need to offer a competitive benefits package for our employees and their families.Learn More